1 The effects of the selective a2-adrenoceptor agonist, medetomidine, were assessed on plasma levels of immunoreactive atrial natriuretic peptide (IR-ANP), haemodynamics and on urine water and solute excretion in conscious, chronically cannulated, 7 month-old spontaneously hypertensive (SHR) and age-matched Wistar-Kyoto (WKY) rats, in order to examine the role of a2-adrenoceptors in the control of ANP secretion.2 A 60min i.v. infusion of medetomidine (0.2 or 0.6.ugkg-1min-') decreased heart rate dosedependently in both strains. Medetomidine infusion (0.6pgkg-1min-1) resulted in an increase in mean arterial pressure in WKY, whereas both doses decreased blood pressure in SHR. There was a slight increase in the right atrial pressure in both strains (WKY: + 1.18 + 0.26 mmHg; SHR: +1.64 + 0.64 mmHg, NS) in response to infusion of 0.6 pg kg-min-of medetomidine. 3 No differences were found in resting plasma IR-ANP levels between WKY (114 + 8 pg ml-, n = 19) and SHR (117 ± 10pgmlP, n = 21). Infusion of equibradycardic doses of medetomidine increased dose-dependently plasma IR-ANP levels in WKY, but did not affect the plasma IR-ANP concentration in SHR rats. 4 Despite the different effect of medetomidine on ANP release in WKY and SHR rats, i.v. administration of medetomidine affected renal excretory functions similarly in both strains; urine flow and sodium excretion increased and urine osmolality decreased significantly, while there was no consistent change in urinary potassium excretion. Urine osmolality decreased to hypo-osmotic levels during the infusion of 0.6 yg kg-1 min1 of medetomidine, suggesting a possible interaction between a2-adrenoceptor stimulation and the vasopressin system. 5 These results show that the a2-adrenoceptor agonist medetomidine increased plasma levels of ANP in WKY rats, probably through an increase in mean arterial and right atrial pressures, whereas the SHR had attenuated ANP release to a2-adrenoceptor stimulation. Our findings, that medetomidine caused marked natriuretic and diuretic effects in both strains and that these effects on the excretory functions of the kidneys were not related to changes in plasma levels of IR-ANP, demonstrate that changes in plasma ANP levels alone do not account for the diuretic and natriuretic effect of x2-agonists.